Nektar Therapeutics Earnings Recaps
Q3 2025
Nov 8, 2025
Nektar Therapeutics reports robust advancements in clinical trials, particularly for rezpegaldesleukin (REZPEG), positioning itself for potential market leadership in atopic dermatitis and alopecia areata.
Key takeaways
- Successfully advanced REZPEG into the Phase III development stage, targeting moderate to severe atopic dermatitis.
- Strong preliminary results from the RESOLVE-AD study, showcasing REZPEG's differentiation from existing treatments, particularly for patients with comorbid asthma.
- Planned presentations of 52-week maintenance data in Q1 and top-line results from alopecia areata studies are expected to further bolster the therapeutic profile.
- Nektar aims to capture a significant portion of the $1 billion alopecia areata market with REZPEG as a potential first biologic therapy.
- Upcoming FDA end-of-Phase II meeting anticipated to discuss Phase III plans for REZPEG in atopic dermatitis.